This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Katsarolis, I.
Right arrow Articles by Giamarellou, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Katsarolis, I.
Right arrow Articles by Giamarellou, H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2000, p. 2564-2566, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Successful Trovafloxacin Prophylaxis against Experimental Streptococcal Aortic Valve Endocarditis

Ioannis Katsarolis,1,* Angelos Pefanis,2 Dimitrios Iliopoulos,3 Peter Siaperas,1 Panagiotis Karayiannakos,3 and Helen Giamarellou1

4th Department of Medicine, Sismanoglion General Hospital,1 3rd Department of Medicine, Sotiria General Hospital for Chest Diseases,2 and Laboratory of Experimental Surgery and Surgical Research,3 Athens University School of Medicine, Athens, Greece

Received 30 December 1999/Returned for modification 17 March 2000/Accepted 19 June 2000

Single-dose trovafloxacin (15 mg/kg given intravenously [i.v.]) and ampicillin (40 mg/kg given i.v.) protected 38 and 33% of animals challenged with an ampicillin-tolerant strain of Streptococcus oralis, respectively. As a double-dose regimen, trovafloxacin afforded total protection (100%; P < 0.001 versus controls). Trovafloxacin is the first fluoroquinolone effective in preventing experimental streptococcal endocarditis.

* Corresponding author. Mailing address: 4th Department of Medicine, Sismanoglion General Hospital, 15126 Athens, Greece. Phone: 30-1-8039542. Fax: 30-1-8039543. E-mail: aikat{at}ath.forthnet.gr.

Antimicrobial Agents and Chemotherapy, September 2000, p. 2564-2566, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Carmona, I. T., Diz Dios, P., Scully, C. (2007). Efficacy of Antibiotic Prophylactic Regimens for the Prevention of Bacterial Endocarditis of Oral Origin. JDR 86: 1142-1159 [Abstract] [Full Text]  
  • Sakka, V., Galani, L., Pefanis, A., Iliopoulos, D., Athanasopoulos, G., Donta, I., Giamarellou, H. (2005). Successful moxifloxacin prophylaxis against experimental streptococcal aortic valve endocarditis. J Antimicrob Chemother 56: 1160-1162 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»